Prestige BioPharma950210 
1.12%24h
Prestige BioPharma (950210) Stock Overview
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
950210 Stock Information
Prestige BioPharma (950210) Price Chart
Prestige BioPharma Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $10.18 | N/A |
| Market Cap | $608.99M | N/A |
| Shares Outstanding | 59.84M | -0.41% |
| Employees | 0 | N/A |
| Shareholder Equity | 546.23B | 27.05% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | 0.03 | N/A |
| P/S Ratio | 4991.64 | N/A |
| P/B Ratio | 0.00 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.0000 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $122.00K | N/A |
| Earnings | -$2.16M | N/A |
| EPS | 293.60 | N/A |
| Earnings Yield | 28.85 | N/A |
| Gross Margin | 1.00 | N/A |
| Operating Margin | 6.59 | N/A |
| Net income margin | -17.66 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $559.05M | N/A |
| Total Debt | $63.60M | N/A |
| Cash on Hand | $227.22M | N/A |
| Debt to Equity | 0.0003 | 120.06% |
| Cash to Debt | $3.57 | -94.99% |
| Current Ratio | $2.31 | -69.02% |
